SpringWorks' non-cancerous tumor drug to be priced at $29,000 per month in US (updated)

SpringWorks Therapeutics

28/11/2023 14:15

(Adds analysts comments on pricing in paragraph 3, details in
paragraph 4)
       Nov 28 (Reuters) - SpringWorks Therapeutics'  SWTX.O 
drug for treating adult patients with a type of rare
non-cancerous soft-tissue tumor will be sold in the U.S. at a
list price of $29,000 for a 30-day supply, the company said on a
conference call on Tuesday.
    The monotherapy branded as Ogsiveo became the first approved
treatment for desmoid tumors — abnormal growths that occur in
connective tissues and are associated with a high rate of
recurrence — following the U.S. health regulator's nod on
Monday.
    H.C. Wainwright analyst Robert Burns expected the drug to be
priced at around $18,000 per month. TD Cowen analyst Yaron
Werber expected the price to be $247,000 for 12 months, which
leads to the per-month price of around $20,583.
    SpringWorks also expects to file a marketing application for
the therapy with the European Medicines Agency (EMA) in the
first half of 2024.

 (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi
Majumdar)
 ((Pratik.Jain@thomsonreuters.com;))